[1]JAISWAL A,CHICHRA A,NGUYEN V Q,et al.Challenges in the management of patients with chronic obstructive pulmonary disease and heart failure with reduced ejection fraction[J].Curr Heart Fail Rep,2016,13(1):30-36.DOI:10.1007/s11897-016-0278-8.
[2]张开进,李兴德.慢性阻塞性肺疾病合并心力衰竭诊治进展[J].心血管病学进展,2018,39(3):398-401.DOI:10.16806/j.cnki.issn.1004-3934.2018.03.024.
ZHANG K J,LI X D.Advances in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure[J].Advances in Cardiovascular Disease,2018,39(3):398-401.DOI:10.16806/j.cnki.issn.1004-3934.2018.03.024.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):67-80.DOI:10.3760/cma.j.issn.1001-0939.2013.04.007.
Chronic Obstructive Pulmonary Disease Group,Society of Respiratory Diseases,Chinese Medical Association.Guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease(2013 revised edition)[J].Chinese Journal of Tuberculosis and Respiratory Diseases,2013,36(4):67-80.DOI:10.3760/cma.j.issn.1001-0939.2013.04.007.
[4]中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,40(2):98-122.
Chinese Society of Cardiology of Chinese Medical Association.Chinese guidelines for the diagnosis and treatment of heart failure 2014[J].Chinese Journal of Cardiology,2014,40(2):98-122.
[5]ORSO F,FABBRI G,BALDASSERONI S,et al.Newest additions to heart failure treatment[J].Expert Opin Pharmacother,2014,15(13):1849-1861.DOI:10.1517/14656566.2014.934812.
[6]CHATTERJEE S,BIONDI-ZOCCAI G,ABBATE A,et al.Benefits of β blockers in patients with heart failure and reduced ejection fraction:network meta-analysis[J].BMJ,2013,346:f55.
[7]张健,张宇辉.多中心、前瞻性中国心力衰竭注册登记研究:病因、临床特点和治疗情况初步分析[J].中国循环杂志,2015,30(5):413-416.
ZHANG J,ZHANG Y H.China heart failure registry study:a multicenter,prospective investigation for preliminary analysis on etiology,clinical features and treatment in heart failure patients[J].Chinese Circulation Journal,2015,30(5):413-416.
[8]STRABURZYSKA-MIGAJ E,KAUNA-OLEKSY M,MAGGIONI A P,et al.Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey(ESC-HF Pilot):polish population[J].Arch Med Sci,2015,11(4):743-750.DOI:10.5114/aoms.2014.47878.
[9]KUBOTA Y,TAY W T,ASAI K,et al.Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failure[J].ESC Heart Fail,2018,5(2):297-305.DOI:10.1002/ehf2.12228.
[10]MCALISTER F A,WIEBE N,EZEKOWITZ J A,et al.Meta-analysis:beta-blocker dose,heart rate reduction,and death in patients with heart failure[J].Ann Intern Med,2009,150(11):784-794.
[11]B?HM M,BORER J,FORD I,et al.Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure:analysis from the SHIFT study[J].Clin Res Cardiol,2013,102(1):11-22.DOI:10.1007/s00392-012-0467-8.